German pharmaceutical giant Merck has announced an agreement to acquire U.S.-based biotechnology company Bio-Techne in a deal valued at approximately $11.3 billion, marking one of the largest life sciences acquisitions of the year.
The transaction reflects the growing race among global healthcare companies to strengthen their positions in biotechnology, diagnostics, and advanced research tools. As the pharmaceutical industry increasingly shifts toward precision medicine and biologic therapies, acquisitions such as this have become an important strategy for expanding technological capabilities and accelerating long-term growth.
Merck has long been recognized as one of Europe’s leading science and technology companies, with operations spanning healthcare, life sciences, and electronics. In recent years, the company has invested heavily in expanding its life sciences division, which provides laboratory equipment, chemicals, and technologies that support pharmaceutical research and manufacturing.
By acquiring Bio-Techne, Merck gains access to a highly respected portfolio of research reagents, diagnostic solutions, protein analysis technologies, and genomic tools that are widely used by pharmaceutical companies, biotechnology firms, and academic researchers around the world.
Register for Tekedia Mini-MBA edition 20 (June 8 – Sept 5, 2026).
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Bio-Techne has established itself as a leader in supplying high-quality products that enable scientists to better understand diseases, discover new drug targets, and develop innovative therapies. Its technologies are particularly valuable in areas such as cancer research, immunology, neuroscience, stem cell biology, and molecular diagnostics.
These fields continue to attract significant investment as healthcare systems increasingly prioritize personalized medicine and treatments tailored to individual patients. The $11.3 billion acquisition is expected to create meaningful synergies between the two companies.
Merck will be able to integrate Bio-Techne’s specialized research tools into its existing life sciences business, offering customers a broader range of products across the entire drug development process. This expanded portfolio could strengthen Merck’s competitive position against major rivals in the global life sciences market while providing customers with more comprehensive laboratory solutions.
Beyond expanding product offerings, the acquisition also provides Merck with opportunities to accelerate innovation. Combining Bio-Techne’s expertise in protein sciences, cell biology, and molecular diagnostics with Merck’s global research, manufacturing, and distribution network could shorten development timelines for new technologies.
Increased collaboration between research teams may also lead to the creation of next-generation laboratory platforms that improve efficiency for scientists working on breakthrough therapies. The timing of the acquisition is significant.
Global demand for biotechnology products continues to grow rapidly, driven by advances in gene therapies, cell therapies, artificial intelligence-assisted drug discovery, and precision diagnostics. Pharmaceutical companies are investing billions of dollars into research programs that require increasingly sophisticated laboratory technologies.
By strengthening its presence in this expanding market, Merck positions itself to benefit from long-term industry trends rather than relying solely on traditional pharmaceutical revenue. Financially, the acquisition represents a substantial commitment, but Merck appears confident that the long-term growth potential justifies the investment.
Analysts generally view life sciences businesses as attractive because they often generate stable revenue through recurring demand from research institutions, pharmaceutical manufacturers, and clinical laboratories.
These businesses also tend to be less vulnerable to the patent expiration cycles that affect traditional drug manufacturers. If regulatory approvals are secured, the transaction will further reshape the competitive landscape of the global biotechnology sector.
It highlights how large pharmaceutical and life sciences companies are increasingly pursuing acquisitions to gain access to innovative technologies instead of developing every capability internally. For Merck, purchasing Bio-Techne represents more than an expansion of its business—it is a strategic investment in the future of biomedical research, precision medicine, and the next generation of healthcare innovation.